Unigene gains preliminary injunction in Fortical case
This article was originally published in Scrip
Executive Summary
Unigene Laboratories has said that Judge Robert Patterson of the US District Court for the Southern District of New York has entered a preliminary injunction, consented to by defendants ApotexInc and Apotex Corp, preliminarily enjoining them from launching any product proposed in their ANDA for a generic version of the innovator's nasal calcitonin product, Fortical (calcitonin salmon rDNA origin), in the US. The generics firm and the innovator have been locked in a patent battle regarding the only Orange Book-listed patent, No 6,440,392.